Verily hooks $1B round amid C-suite shuffle

Nicole DeFeudis

Editor

Verily, Alphabet’s rather secretive life sciences outfit, is riding a $1 billion cash infusion to its “next phase of growth” — and that necessitates a C …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Verily hooks $1B round amid C-suite shuffle

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Ver­i­ly hooks $1B round amid C-suite shuf­fle

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Verily hooks $1B round amid C-suite shuffle